High-profile mergers regularly occur in the industry as a whole, as large pharmaceutical companies continue to consolidate to maximize research capacity and marketing power. According to industry sources, the 10 largest pharmaceutical firms accounted for more than 58% of total prescription drug sales in 2002.
The very success of these mega-pharmaceutical companies leaves attractive openings for a breed of smaller, specialty pharmaceutical companies that target proven products that may be lacking attention from their developers. Many of these products have become available to specialty companies for sale and/or licensing, and more are expected to appear. Specialty pharma companies are acquiring some of these products as part of a multidimensional growth strategy. In addition, a growing number of specialty companies have internal development capabilities. They may not go back to the molecule, but they are taking well-known products and reformulating them through proprietary technologies and reintroducing them into niche or specialty markets with great success.
Adrian Adams. President and CEO, Kos Pharmaceuticals Inc., Miami; Kos Pharmaceuticals is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing, and marketing proprietary prescription products for the treatment of chronic diseases. For more information, visit kospharm.com.
Carol A. Ammon. CEO, chairman, and director; Endo Pharmaceuticals Inc., Chadds Ford, Pa.; Endo is a fully integrated specialty pharmaceutical company with market leadership in pain management products. For more information, visit endo.com.
Vicente Anido Jr., Ph.D. President and CEO, Ista Pharmaceuticals, Irvine, Calif.; Ista is a specialty pharmaceutical company focused on the development and commercialization of unique and uniquely improved ophthalmic products. For more information, visit istavision.com.
Robert J. Bitterman. President, Dermik Laboratories Inc., VP, Aventis Dermatologicals, Berwyn, Pa.; Dermik provides product innovations to treat a wide range of skin problems, including acne, nail fungus, precancerous lesions, dermatitis, eczema, psoriasis, and rosacea. For more information, visit dermik.com.
John H. Bullion. CEO, Orphan Medical Inc., Minnetonka, Minn.; Orphan Medical acquires, develops, and markets products of high medical value for patients within selected market segments. For more information, visit orphan.com.
J. Melville Engle. President and CEO, Dey LP, Napa, Calif.; Dey is a specialty pharmaceutical company focused on the development, manufacturing, and marketing of prescription drug products for the treatment of respiratory diseases and respiratory related allergies. Dey is an affiliate of EMD Inc., which is part of Merck KGaA. For more information, visit dey.com.
Michael Friedman. President and CEO, Purdue Pharma LP, Stamford, Conn.; Purdue Pharma and its independent U.S. associated companies are known for their pioneering research on a principal cause of human suffering: persistent pain. For more information, visit purduepharma.com.
James R. Howard-Tripp. President and CEO, Labopharm Inc., Laval, Quebec, Canada; Labopharm is an international specialty pharmaceutical company focused on the development of drugs incorporating the company’s proprietary advanced controlled-release technology, Contramid. For more information, visit labopharm.com.
A.J. Kazimi. CEO, Cumberland Pharmaceuticals Inc., Nashville, Tenn.; Cumberland Pharmaceuticals is a specialty pharmaceutical company with a mission to acquire rights to branded prescription products and grow them through marketing to targeted physician segments. For more information, visit cumberlandpharma.com.
Thomas H. McLain. President and CEO, Nabi Biopharmaceuticals, Boca Raton, Fla.; Nabi discovers, develops, manufactures, and markets products that power the immune system to help people with serious, unmet medical needs. For more information, visit nabi.com.
Bruce A. Peacock. President and CEO, Adolor Corp., Exton, Pa.; Adolor is a late-stage biopharmaceutical company committed to the development and commercialization of novel products to relieve pain and reduce the side effects of currently marketed narcotics. For more information, visit adolor.com.
Richard F. Pops. CEO, Alkermes Inc., Cambridge, Mass.; Alkermes is an emerging pharmaceutical company developing products based on sophisticated drug-delivery technologies to enhance therapeutic outcomes. For more information, visit alkermes.com.
Jonah Shacknai. Chairman, CEO, and founder, Medicis, Scottsdale, Ariz.; Medicis is a leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatologic, pediatric, and podiatric conditions. For more information, visit medicis.com.
Dennis L. Smith. President and CEO, INO Therapeutics Inc., Clinton, N.J.; INO Therapeutics, a division of AGA Linde Healthcare, is a global speciality care pharmaceutical company committed to developing and marketing treatments in the areas of heart and lung function. For more information, visit inotherapeutics.com.
Philip S. Tabbiner. President and CEO, aaiPharma Inc., Wilmington, N.C.; aaiPharma is a science-based specialty pharmaceutical company that is focused on acquiring, improving, and marketing well-known, branded medicines in pain management, gastroenterology, and critical care. For more information, visit aaipharma.com.